Infinity Pharma

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development segment. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.

NEW YORK , Feb. 27, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), relating to its proposed merger with MEI Pharma, Inc.. Under the terms of the agreement, INFI shareholders are expected to own approximately 42% of the newly combined company.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Infinity Pharmaceuticals, Inc. - INFI

MEI Pharma

MEI Pharma and Infinity Pharmaceuticals announced a merger. These are the details.

MEI Pharma And Infinity Pharmaceuticals Announce Merger (MEIP) (INFI)

NEW YORK , Feb. 23, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and its board of directors concerning the proposed acquisition of the company by MEI Pharma, Inc. (NASDAQ: MEIP). Infinity Pharmaceutical stockholders are expected to own 42% of the combined company.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.

MILWAUKEE , Feb. 23, 2023 /PRNewswire/ -- Ademi LLP is investigating Infinity (NASDAQ: INFI) for possible breaches of fiduciary duty and other violations of law in its transaction with MEI Pharma.  Click here to learn how to join the action https://www.ademilaw.com/case/infinity-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Infinity Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with MEI Pharma

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and MEI Pharma, Inc. is fair to Infinity shareholders. Per the merger agreement, pre-merger MEI shareholders are expected to own approximately 58.0% and pre-merger Infinity shareholders are expected to own approximately 42.0% of the outstanding equity of the combined company immediately following the merger.

INFI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Infinity Pharmaceuticals, Inc. Is Fair to Shareholders

SAN DIEGO, CA. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc.

MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34th Annual Healthcare Conference taking place November 29 – December 1, 2022 in New York.

Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference

The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and Chief Executive Officer Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Edward Tenthoff - Piper Sandler Soumit Roy - Jones Research Mayank Mamtani - B. Riley Operator Ladies and gentlemen, thank you for standing by.

Infinity Pharmaceuticals, Inc. (INFI) Q3 2022 Earnings Call Transcript

Infinity (INFI) delivered earnings and revenue surprises of -140% and 91.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provided a business update, and in a separate press release provided more mature data from the Phase 2 MARIO-3 1L TNBC clinical trial.

Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today reported an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple negative breast cancer (TNBC) patients.

Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib

Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference. 2022 Wells Fargo Healthcare Conference Date: Frida

Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences

Start Time: 16:30 January 1, 0000 4:58 PM ET Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 PM ET Company Participants Adelene Perkins - Chair and CEO Robert Ilaria - CMO Larry Bloch - President Jayne Kauffman - Senior Executive Coordinator Conference Call Participants Edward Tenthoff - Piper Sandler Robyn Karnauskas - Truist Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company's Second Quarter 2022 Financial Results and Business Update.

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q2 2022 Results - Earnings Call Transcript

Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 1.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2022 financial results, unveiled new positive data from the Phase 2 MARIO-275 clinical trial, and provided a business update. “Today, we are pleased to announce positive survival data that shows approximately a d

Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, August 9th, 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022. Conference Call & Webcast Details Date: Tuesday, August 9th   Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com/mmc/p/ci3

Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022. H.C. Wainwright Global Investment Conference Presentation (hybrid) Date: Tuesday, May 24th

Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and CEO Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Anupam Rama - JPMorgan Nick Abbott - Wells Fargo Soumit Roy - Jones Research Operator Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the company's operations and First Quarter 2022 Financial Results.

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q1 2022 Results - Earnings Call Transcript

Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its first quarter 2022 financial results and provided a corporate update. “We are pleased to further advance the development of eganelisib, building on our encouraging MARIO-3 results, by initiating our first registration study, MA

Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial results for the first quarter of 2022. Conference Call & Webcast Details Date: Tuesday, May 3rd Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com/mmc/p/prmegw6b Tol

Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast

Axsome Therapeutics

Werewolf Therapeutics

Jazz Pharmaceuticals

Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.

JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, granted non-statutory stock options to two new employees on April 6, 2022. The grants were previously approved by the Inducement Grant Subcommittee of the Compensation Committee of its Board of Directors and were made as inducement awards outside the Company's 2019

News for Infinity Pharma Stock (INFI)